T1	p 51 153	of previously untreated advanced breast cancer -- a cancer and leukemia group B study ( CALGB 8642 ) .
T2	p 536 731	the Cancer and Leukemia Group B ( CALGB ) master metastatic breast cancer protocol . CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of several Phase II
T3	p 1279 1333	histologically documented measurable breast cancer and
T4	p 1355 1382	of 0-1 . Patients could not
T5	p 1392 1435	prior chemotherapy for metastatic disease .
T6	p 2305 2329	breast cancer patients .
T7	i 6 17	Amonafide :
T8	i 21 27	active
T9	i 193 208	naphthalic acid
T10	i 788 796	standard
T11	i 849 868	immediate treatment
T12	i 874 926	standard cyclophosphamide-doxorubicin-5-fluorouracil
T13	i 1072 1102	precedes standard chemotherapy
T14	i 1451 1463	chemotherapy
T15	i 2252 2261	amonafide
T16	o 988 1030	survival , toxicity , and overall response
T17	o 1504 1521	visceral crisis .
T18	o 1657 1666	reduction
T19	o 1716 1742	or lack thereof . Toxicity
T20	o 1757 1770	hematological
T21	o 1805 1817	4 leukopenia
T22	o 1842 1860	4 thrombocytopenia
T23	o 1875 1885	leukopenia
T24	o 1902 1938	thrombocytopenia . The response rate
T25	o 1964 1983	complete response .
T26	o 1989 1997	response
T27	o 2014 2036	hematological toxicity
T28	o 2083 2103	leukopenia grade 3/4
T29	o 2176 2202	thrombocytopenia grade 3/4
T30	o 2351 2364	dose-response
T31	o 2418 2468	myelosuppression and response . Rates of responses